Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Advanced Micro Devices

organization80% conf.·synced Oct 15, 2026

Competitor to Intel in x86 server market

60
sourced metrics
822
relationships
20
stated objectives
1
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week Low
190.95USD
Oct 14, 2026reference only
Price 52 Week High
649.42USD
Oct 14, 2026reference only
Stock Return Ytd
155.4%
Oct 14, 2026reference only
Stock Price
570.82USD
Oct 14, 2026reference only
Market Cap
931849403474USD
Oct 14, 2026reference only
Shares Outstanding
1632475042.0shares
Jul 29, 2026reference only
Operating Income
1990000000.0USD
Jun 27, 2026reference only
Cost Of Revenue
5333000000.0USD
Jun 27, 2026reference only
Total Assets
84464000000.0USD
Jun 27, 2026reference only
Gross Profit
6203000000.0USD
Jun 27, 2026reference only
Eps
1.38USD_per_share
Jun 27, 2026reference only
Revenue
11536000000.0USD
Jun 27, 2026reference only
Net Income
2297000000.0USD
Jun 27, 2026reference only
Stockholders Equity
67224000000.0USD
Jun 27, 2026reference only
Rd Expense
2528000000.0USD
Jun 27, 2026reference only
Cash
5086000000.0USD
Jun 27, 2026reference only
Operating Cash Flow
2955000000.0USD
Mar 28, 2026reference only
Capex
389000000.0USD
Mar 28, 2026reference only

Stated objectives

60% jump in data center revenue

source
target: 60% stated

Grow by 35% per year for next 3-5 years due to AI demand

source
target: 35 stated

Q4 2025 revenue guidance

source
target: 9.6 billion USD by 2025-12-31 00:00:00stated

Q4 2025 gross margin guidance

source
target: 54.5% by 2025-12-31 00:00:00stated

Analysts expect 28-35% annual revenue growth through 2027 driven by AI and data center demand

source
target: 28-35% YoY by 2027-12-31 00:00:00stated

Market pricing implies 35-40% EPS growth in coming years

source
target: 35-40% EPS growth stated

AMD targets approximately 35% annual revenue/earnings growth driven by insatiable AI demand

source
target: 35% per year stated

Grow Data Center segment revenue by more than 60% annually

source
target: >60% annual growth stated

Scale AI business to tens of billions in annual revenue

source
target: tens of billions USD annually by 2027-01-01 00:00:00stated

Grow total company revenue at greater than 35% CAGR over the next 3 to 5 years

source
target: >35% CAGR stated

Relationship graph · 822 connections

Competes with
235
Supplies to
191
Developed by
121
Covered by
73
Customer of
53
Invested in
30
Employs
25
rates
15
acquired by
MEXTZT Systems

Via News coverage

Europe's Flagship AI Lab Runs on Someone Else's Chips — And the Trust Behind Agentic AI Hasn't Caught Up
August 31, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com